Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1632 1654 1656 1678 1759
This examiner grants 66% of resolved cases
Examiner JAE W LEE is assigned to Tech Center 1700 and Art Unit 1632. The examiner has reached a final resolution on 420 cases. The data shows an allowance rate of 65.7 percent, which represents the proportion of applications that result in a patent grant rather than an abandonment. This rate provides a primary indicator of the likelihood of success for an application assigned to this examiner in Art Unit 1632.
The median days to allowance for this examiner is 1222. This figure represents the middle point of the time distribution for applications that successfully result in a patent grant. A median of 1222 days offers a specific timeline for practitioners to consider when managing client expectations and filing strategies. Understanding this duration is essential for navigating the procedural requirements of Tech Center 1700.
The interview lift is 39.0 percent. This figure quantifies the change in the probability of allowance when an interview is conducted during the prosecution process. A lift of 39.0 percent suggests that verbal communication with the examiner may influence the final outcome of a case. For the 420 resolved cases analyzed, this statistic serves as a tool for determining whether to request a formal interview.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18267024 | METHODS AND MATERIALS FOR TREATING PROSTATE CANCER | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18021693 | SHANK3 GENE THERAPY APPROACHES | Final Rejection | Massachusetts Institute of Technology |
| 17786168 | GENOME EDITING USING REVERSE TRANSCRIPTASE ENABLED AND FULLY ACTIVE CRISPR COMPLEXES | Final Rejection | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 17816637 | TRANSFORMATIONAL IMMUNE DIAGNOSTICS | Non-Final OA | Arizona Board of Regents on Behalf of Arizona State University |
| 18696730 | MR-PROADM MARKER PANELS FOR EARLY DETECTION OF SEPSIS | Non-Final OA | Roche Diagnostics Operations, Inc. |
| 17997453 | ALBUMIN DRUG CONJUGATES AND USE THEREOF FOR THE TREATMENT OF CANCER | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18507493 | METHODS AND COMPOSITIONS FOR TREATMENT OF VIRAL INFECTION | Non-Final OA | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED |
| 18124822 | SYSTEMS AND METHODS FOR THE BINDING OF RARE EARTH ELEMENTS BY BETA ROLL PEPTIDES | Non-Final OA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 17905583 | IN VIVO mRNA DISPLAY: LARGE-SCALE PROTEOMICS BY NEXT GENERATION SEQUENCING | Final Rejection | The Trustees of Columbia University in the City of New York |
| 18601534 | ALPHA-AMYLASE VARIANTS | Non-Final OA | Novozymes A/S |
| 17927164 | SUBTILASE VARIANTS AND COMPOSITIONS COMPRISING SAME | Final Rejection | Novozymes A/S |
| 18040810 | CELLULOSE BINDING DOMAIN (CBD) CELL EFFECTOR PROTEIN (CEP) CHIMERA, FOR THE TISSUE ENGINEERING | Non-Final OA | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
| 18065810 | NOVEL MICROORGANISM FOR POLYSTYRENE BIODEGRADATION | Non-Final OA | INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy